MOBOCERTINIB (EXKIVITY) Nursing Considerations

Join NURSING.com to watch the full lesson now.

Included In This Lesson

Outline

What is the generic name?

MOBOCERTINIB

What is the Trade Name for MOBOCERTINIB?

EXKIVITY

What are the Indications for MOBOCERTINIB?

  • 1 INDICATIONS AND USAGE EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] , whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 , 2.1 )

 

View Our Nursing Pharmacology Course


 

References: https://open.fda.gov/

 

Other Pharm Resources
Join NURSING.com to watch the full lesson now.